Abstract
To illustrate the variable clinical presentations and rates of progression in familial hypertrophic cardiomyopathy (FHC), phenotypes and genotypes were compared in three FHC families with different genetic defects. In the first family, the FHC abnormality was a protein truncating mutation (Gln969X) in Penetrance calculations in the three families studied confirm that the clinical heterogeneity associated with FHC is considerable. The calculation of penetrance can be difficult. In FHC, this is related to the subjective nature of the clinical criteria and, in the present study, its cross sectional nature. In the case of family F155, the identification of a recently acquired de novo mutation8 has meant that the number of generations available for study is limited. Nevertheless, in family F237, it is apparent that the natural history of FHC, in terms of disease progression as measured by penetrance, is that of a milder disorder. The findings of DNA heterogeneity in FHC have raised the possibility that different DNA defects might be associated with specific clinical manifestations of this disorder. Some mutations in the cardiac 0 myosin heavy chain gene (for example, Arg4O3Gln) have been reported to have a high association with sudden death, while others (for example, Val6O6Met) a low risk of death. This has given rise to the concept of "benign" and "malignant" mutations.715 However, the reliability of this classification has been questioned with a number of exceptions now observed.'6 Based on sudden cardiac death, the Gln969X mutation in family F237 might be considered "malignant", yet others in the family have experienced minimal clinical consequences of this disorder. Explanations for clinical variability have also been related to the underlying protein abnormality, for example, truncated proteins (the Gln969X mutation found in family F237) can produce their effect through a reduction in the net amount of functional protein (haploinsufficiency). Missense changes (the Asn755Lys and Arg453Cys mutations) can function in autosomal dominant disorders through a dominant negative mechanism. In the three families studied, more complete penetrance was observed in two missense mutations compared to the one truncating defect. However, as stated previously, phenotype/genotype correlations in the more extensively characterised missense changes have not produced definitive trends to date. Thus, at the present time, it is not possible to correlate the underlying mutation with the clinical outcome, particularly in respect to hypertrophy and progression of disease. More data are required before the use of DNA mutation analysis, in this aspect of patient management, can be assessed.
The distinctive pathological changes which occur in FHC include ventricular hypertrophy and myocyte and myofibrillar disarray. Cellular disarray may be a critical factor in sudden cardiac death resulting from a ventricular tachyarrhythmia. There is discrepancy between the severity of hypertrophy and cellular disarray. Subjects with ventricular tachyarrhythmias do not always have obvious ventricular hypertrophy.4 17 18 Another explanation for heterogeneity is that FHC is a multifactorial or polygenic disorder, with the full phenotypic expression reliant on the interaction of the environment or other genes or both." Results from the present study are consistent with FHC being a complex genetic disorder, since all three families show considerable clinical heterogeneity despite the same DNA mutation being shared among family members.
Considerable debate has occurred in respect to the DNA testing of children for adult onset disorders, including FHC, although there does not appear to be any objection to screening children with the conventional clinical means.'9 20 21 However, since the clinical approaches are not always helpful, even in adults, it is not surprising that alternative diagnostic tests are in demand. Unlike other adult onset disorders, such as Huntington's disease or familial adenomatous polyposis, children with FHC can develop life threatening complications, even though their parents are normal or mildly affected. This is illustrated in family F237, with the sudden death of an offspring of a parent whose FHC clinical status was equivocal. Under these circumstances, the issues of discrimination and the effect that DNA test results may have on a child's subsequent development need to be balanced with the potential serious clinical outcomes if all available information, including DNA mutation analysis, is not obtained.
In practical terms, the molecular heterogeneity found in FHC means that DNA testing is difficult and, with current technology, not useful in the majority of families."3 However, for those families in which a mutation can be found, it is possible to exclude from subsequent follow up a number of people. Resources can then be focused on those who remain at risk. Although the association of exercise with sudden death is well known in FHC and occurred in families F237 and F155, it is relevant to note that at present there are no completely reliable clinical parameters which accurately predict this fatal complication.' Nevertheless, a child who is shown to be DNA mutation positive may benefit from the avoidance of competitive sports and certain medications, such as the sympathomimetics, which might increase the risk of sudden death. The child would also warrant closer medical supervision and follow up. This is particularly relevant now that treatment with implantable defibrillators is available for those who have ventricular tachyarrythmias. In the context of a research proposal, the potential to follow prospectively children who are mutation positive is important to understand the natural history of FHC. In view of the complexities found in FHC, it is essential that a team approach (geneticist, counsellor, cardiologist, and molecular geneticist) is adopted in its clinical management, so that a comprehensive and effective counselling service can be offered. 
